Basu PK. Pharmaceutical process development is different. Chem Eng Prog 1998;94:75–82.
Pisano G. The development factory: unlocking the potential of process innovation. Boston: Harvard Business School Press; 1997.
Leila A, Henry S. New prescriptions for drug makers: update the plants. Wall Street Journal, September 12, 2003.
US Department of Health and Drug Administration. Challenge and opportunity on the critical path to new medical products. Rockville: US Department of Health and Drug Administration; 2004. March.
Cohen N. PAT: process analytical technology as FDA and industry effort. In: ISPE Midwest Chapter Meeting, 2005.
Hussain A. The process analytical technology initiative: PAT and pharmacopeias. In: EDQM Spring Conference, Cannes, 2004.
Hussain A. ACPS Meeting, 2001.
Woodcock J. Issues in drug quality regulation. March 12, 2002.
NIPTE. Strategic roadmap for pharmaceutical technology. Des Plaines: NIPTE; 2008.
Vernon JA, Hughen KW, Trujilli AJ. Pharmaceutical manufacturing efficiency, drug prices, and public health: examining the casual links. Drug Information J. 2007;41:229–39.
Dimasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–85.PubMedCrossRef
Dimasi JA, Hansen RW, Grabowski HG. Cost of innovation in the pharmaceutical industry. J Health Econ. 1991;10:107–42.PubMedCrossRef
Adams C, Brantner VV. Estimating the costs of new drug development: is it really $802 million. Health Aff 2006;25:420–8.CrossRef
Matthews M Jr. From inception to ingestion: the cost of creating new drugs, ideas. Bradford: Institute of Pharmaceutical Innovation; 2001. September.
Gilbert J, Singh A, Henske P. Rebuilding Big Pharma’s business model. In ViVo 2003;21:10. November, windhover.com.
Grabowski HG, Vernon JA, Dimasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics. 2002;20(Suppl 3):11–29.PubMedCrossRef
Dickson M, Gagnon JP. The cost of new drug discovery and development. Discov Med. 2001;4:172–9. June.
Said HC. New frontiers in pharma R&D and India’s strengths in new drug discovery. In INDIA CHEM 2002; 2003 (Former Managing Director, Pfizer India).
Tollman P, Guy P, Altshuller J, et al. A revolution in R&D: how genomics and genetics will affect drug development costs and times. In: B. C. Group, editor. Pharmaceutical R&D statistical sourcebook. Boston: BCG; 2002–2003.
McCormick K. Manufacturing in global pharmaceutical industry. London: Urch; 2003.
Benson RS, McCabe JDJ. From good manufacturing practices to good manufacturing performance. Pharmaceutical Engineering 2004;24:26–34. July/August.
Raju GK. FDA Science Board Meeting. 2001.
Dean D, Bruttin F. Armonk: Metamorphosis of manufacturing; IBM Business Consulting Services; 2005.
Hussain A. Final report on PAT and manufacturing science. In FDA Science Board Meeting, 2004.
Migliaccio G. FDA will seek consultant help in implementing quality initiative. The GoldSheet, vol. 36, September 2002.
Dean D, Bruttin F. The risks and economics of regulatory compliance. PDA J Pharm Sci. 2000;54:253–63. May–Jun.
Reinhardt UE. Perspectives on the pharmaceutical industry. Health Aff. 2001;20:136–49. September/October.CrossRef
Basu PK, Joglekar G, Rai S, Suresh P, Vernon JA. Analysis of manufacturing costs in pharmaceutical companies. J Pharmaceut Innov. 2008;3:30–40. March.CrossRef
Holcomb M, Rutten P, Fuhr T, Basu PK. Value of implementing quality by design for the pharmaceutical industry. Rockville: FDA; 2008.
Codgill RP, Knight TP, Anderson CA, Drennen JK. The financial returns on investments in process analytical technology and lean manufacturing: benchmarks and case study. J Pharmaceut Innov. 2007;2:38.CrossRef